Renata PLC expands global reach with UK launch of Cabergoline
Renata PLC is excited to announce the successful shipment of its first consignment of Cabergoline 0.5 mg tablets to the UK market.
This milestone follows the launch of the first generic Cabergoline 0.5 mg in Australia, marking Renata's continued expansion into key global markets.
Cabergoline, indicated for treating hyperprolactinemia and Parkinson's disease, is also marketed locally under the brand name Cabolin and manufactured at Renata's state-of-the-art, UK MHRA-approved facility in Bangladesh.
Thereby, Renata ensures medicines manufactured under stringent quality control are available as accessible healthcare solutions to patients locally and worldwide.
Keep updated, follow The Business Standard's Google news channel
The initial shipment comprised 160,000 tablets. Renata's launch of Cabergoline 0.5mg in the UK marks its commitment to strengthening its presence in highly regulated markets while demonstrating expertise in developing and delivering low-dose, high-potency complex products.
Through its innovative product portfolio and global partnerships, Renata PLC remains dedicated to enhancing patient care and addressing critical healthcare needs worldwide.
